Pharmacokinetics of tenofovir given as two different prodrugs

12 Apr 2023
12 Apr 2023

In the most recent publication from our team, Kawuma et al. employ a modelling approach

to characterize tenofovir’s pharmacokinetics when it is administered as two different prodrugs (TDF vs TAF). They developed a joint semi-mechanistic model that describes the population pharmacokinetics of tenofovir and which can foster further investigation of the use of the TAF prodrug. This model provides a framework for exposure predictions in patients, investigation of drug-drug interactions and simulation of alternative dosing regimens for further clinical trials that may be needed in the African context (for example within individuals co-infected with tuberculosis). 

The publication can be found here.